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Microbial culturomics
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Abstract: Microbial culturomics is a new approach in the bio-
logical exploration strategies of the XXI century. By multiplying
the isolation strategies, identify quickly by MALDI-TOF techniques
and identify bacteria in non identiﬁed MALDI-TOF database, by
sequencing the16S rDNAgene. Comparing the culturomics on sam-
ples of digestive origin shows that it has a performance comparable
to that of metagenomics with only 15% of bacteria found in com-
mon by metagenomics and the culturomics. In my lab we have
testedmore than700000bacterial colonieswhichhelpedﬁndmore
different bacteria species in our laboratory than in all other labora-
tories in all theworld combined this strategy. This strategywas also
applied to the skin, urinary and vaginal microbiota with prelimi-
nary work that shows results as extremely important to increase
theknownbacterial repertoire. The culturomicsplays a very impor-
tant role in identifying the repertoire of genes associated with
mucosae and provides bacterial isolates for future experimental
models, and future therapeutic strategies.
http://dx.doi.org/10.1016/j.ijid.2016.02.091
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Point of care testing for global health
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Abstract: “Faster, better, cheaper” is amuchbandied term in the
contextof POCT. This talkwill start bydescribing those technologies
which either are beginning, or look to be, capable of really deliver-
ing such promises. The opportunities offered by modern wireless
communications and IT in this space will also be discussed. The
majority of the talk, however, will concentrate on the cloud behind
the silver lining: speciﬁcally, the very real barriers posed by the
“innovationgap”betweenagood idea anda tractable, realistic solu-
tion which needs to be provided by Industry pull-through; and the
oftenneglected but crucial relevance and challenges set by issues of
clinical Governance, poverty, whole healthcare systems, and the all
too commonly ignored concept of “clinical value” – the latter relat-
ing to making sure that whatever you measure in such a modern
and elegant way actually beneﬁts the patient.
http://dx.doi.org/10.1016/j.ijid.2016.02.092
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Whole genome sequencing in diagnostic
microbiology
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Polio eradication: End game and beyond
T.J. John
Christian Medical College, Vellore, India
Abstract: In 2013, the target of polio eradicationwas broadened
to include wild and vaccine polioviruses. In the “Polio Eradication
and End Game Strategic Plan 2013-18” eradication refers to wild
polioviruses (WPVs) and endgame refers tomanaging all risks from
vaccine polioviruses. WPVs can be eradicated using oral poliovac-
cine (OPV). Inactivated poliovaccine (IPV) is necessary to eradicate
vaccine polioviruses.
Attenuation meant drastic reductions in neuro-virulence and
transmission efﬁciency. Vaccine viruses are genetically unstable
and tend to de-attenuate during replication. One risk of pre-
dictable but low frequency is ‘vaccine-associated paralytic polio’
(VAPP) in the vaccinated or in those who get secondarily infected.
Another risk of unpredictable frequency is the generation of
highly transmissible neuro-virulent ‘vaccine-derived polioviruses’
(VDPV). Circulating VDPVs (cVDPVs) are wild-like, causing polio
outbreaks unless interrupted from circulation. Vaccine viruses can
cause chronic intestinal infection in personswith B cell immunode-
ﬁciency; during prolonged infection immunodeﬁciency-associated
VDPV (iVDPV) emerges.
Since 2011, annually VAPP and cVDPV cases outnumber WPV
cases – this is ethically untenable. So OPV must be discontinued.
Immediately VAPP will stop. But IPV cover is essential for with-
drawing OPV, since immunity gap in the community is the major
risk-factor of emergence of cVDPVs. Unless that gap is covered by
IPV, withdrawing OPV will surely lead to uncontrolled polio out-
breaks due to cVDPVs.
WPV-2was eradicated in 1999.Most cVDPV outbreaks and one-
third VAPP are caused by type 2. So, type 2 vaccine virus will be
withdrawn ﬁrst. All OPV-using countries have introduced IPV in
preparationofwithdrawing vaccine type2 inApril 2016. Thereafter
only bivalent OPV (bOPV) containing types 1 and 3will be available
globally. This exercise is also rehearsal for withdrawing bOPV after
